PMID- 31158526
OWN - NLM
STAT- MEDLINE
DCOM- 20200701
LR  - 20240214
IS  - 1943-7811 (Electronic)
IS  - 1525-1578 (Print)
IS  - 1525-1578 (Linking)
VI  - 21
IP  - 5
DP  - 2019 Sep
TI  - A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for 
      Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms.
PG  - 782-789
LID - S1525-1578(19)30076-5 [pii]
LID - 10.1016/j.jmoldx.2019.04.006 [doi]
AB  - Human leukocyte antigen (HLA) alleles have been implicated as risk factors for 
      immune-mediated adverse drug reactions. The authors recently reported a strong 
      association between HLA-A*32:01 and vancomycin-induced drug reaction with 
      eosinophilia and systemic symptoms. Identification of individuals with the risk 
      allele before or shortly after the initiation of vancomycin therapy is of great 
      clinical importance to prevent morbidity and mortality, and improve drug safety 
      and antibiotic treatment options. A prerequisite to the success of 
      pharmacogenetic screening tests is the development of simple, robust, 
      cost-effective single HLA allele test that can be implemented in routine 
      diagnostic laboratories. In this study, the authors developed a simple, real-time 
      allele-specific PCR for typing the HLA-A*32:01 allele. Four-hundred and 
      fifty-eight DNA samples including 30 HLA-A*32:01-positive samples were typed by 
      allele-specific PCR. Compared with American Society for Histocompatibility and 
      Immunogenetics-accredited, sequence-based, high-resolution, full-allelic HLA 
      typing, this assay demonstrates 100% accuracy, 100% sensitivity (95% CI, 88.43% 
      to 100%), and 100% specificity (95% CI, 99.14% to 100%). The lowest limit of 
      detection of this assay using PowerUp SYBR Green is 10 ng of template DNA. The 
      assay demonstrates a sensitivity and specificity to differentiate the HLA-A*32:01 
      allele from closely related non-HLA-A*32 alleles and may be used in clinical 
      settings to identify individuals with the risk allele before or during the course 
      of vancomycin therapy.
CI  - Copyright (c) 2019 American Society for Investigative Pathology and the Association 
      for Molecular Pathology. Published by Elsevier Inc. All rights reserved.
FAU - Rwandamuriye, Francois X
AU  - Rwandamuriye FX
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, 
      Western Australia, Australia.
FAU - Chopra, Abha
AU  - Chopra A
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, 
      Western Australia, Australia; Division of Infectious Diseases, Vanderbilt 
      University Medical Center, Nashville, Tennessee.
FAU - Konvinse, Katherine C
AU  - Konvinse KC
AD  - Department of Pathology, Microbiology and Immunology, Vanderbilt University 
      Medical Center, Nashville, Tennessee.
FAU - Choo, Linda
AU  - Choo L
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, 
      Western Australia, Australia.
FAU - Trubiano, Jason A
AU  - Trubiano JA
AD  - Department of Pathology, Microbiology and Immunology, Vanderbilt University 
      Medical Center, Nashville, Tennessee; Department of Infectious Diseases and 
      Centre for Antibiotic Allergy and Research, Austin Health, Heidelberg, Victoria, 
      Australia; Department of Medicine, University of Melbourne, Parkville, Victoria, 
      Australia.
FAU - Shaffer, Christian M
AU  - Shaffer CM
AD  - Division of Clinical Pharmacology, Vanderbilt University Medical Center, 
      Nashville, Tennessee.
FAU - Watson, Mark
AU  - Watson M
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, 
      Western Australia, Australia.
FAU - Mallal, Simon A
AU  - Mallal SA
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, 
      Western Australia, Australia; Division of Infectious Diseases, Vanderbilt 
      University Medical Center, Nashville, Tennessee; Department of Pathology, 
      Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, 
      Tennessee.
FAU - Phillips, Elizabeth J
AU  - Phillips EJ
AD  - Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, 
      Western Australia, Australia; Department of Medicine, Vanderbilt University 
      Medical Center, Nashville, Tennessee; Department of Pharmacology, Vanderbilt 
      University Medical Center, Nashville, Tennessee. Electronic address: 
      elizabeth.j.phillips@vanderbilt.edu.
LA  - eng
GR  - F30 AI131780/AI/NIAID NIH HHS/United States
GR  - T32 GM007347/GM/NIGMS NIH HHS/United States
GR  - P50 GM115305/GM/NIGMS NIH HHS/United States
GR  - P30 AI110527/AI/NIAID NIH HHS/United States
GR  - R21 AI139021/AI/NIAID NIH HHS/United States
GR  - R34 AI136815/AI/NIAID NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20190531
PL  - United States
TA  - J Mol Diagn
JT  - The Journal of molecular diagnostics : JMD
JID - 100893612
RN  - 0 (Anti-Bacterial Agents)
RN  - 0 (HLA-A Antigens)
RN  - 6Q205EH1VU (Vancomycin)
SB  - IM
MH  - Alleles
MH  - Anti-Bacterial Agents/*adverse effects
MH  - Base Sequence
MH  - Drug Hypersensitivity Syndrome/*diagnosis/etiology/genetics
MH  - Eosinophilia/chemically induced/*diagnosis/genetics
MH  - Genetic Testing/*methods
MH  - HLA-A Antigens/*genetics
MH  - Humans
MH  - Polymerase Chain Reaction
MH  - Sequence Homology
MH  - Vancomycin/*adverse effects
PMC - PMC6734857
EDAT- 2019/06/04 06:00
MHDA- 2020/07/02 06:00
PMCR- 2020/09/01
CRDT- 2019/06/04 06:00
PHST- 2019/02/04 00:00 [received]
PHST- 2019/03/13 00:00 [revised]
PHST- 2019/04/02 00:00 [accepted]
PHST- 2019/06/04 06:00 [pubmed]
PHST- 2020/07/02 06:00 [medline]
PHST- 2019/06/04 06:00 [entrez]
PHST- 2020/09/01 00:00 [pmc-release]
AID - S1525-1578(19)30076-5 [pii]
AID - 10.1016/j.jmoldx.2019.04.006 [doi]
PST - ppublish
SO  - J Mol Diagn. 2019 Sep;21(5):782-789. doi: 10.1016/j.jmoldx.2019.04.006. Epub 2019 
      May 31.